New progress in clinical research of compound naphthoquine phosphate tablets

It is understood that the compound naphthoquine phosphate tablet (Arco ®) is an oral preparation exclusively produced by the company for the treatment of malaria The results of the Indonesian children's clinical study of the compound naphthoquine phosphate tablet (Arco ®) released this time further confirmed the safety and effectiveness of the compound naphthoquine phosphate tablet (Arco ®) in the treatment of various children's malaria on the basis of the good clinical effect of adults Industry insiders pointed out that malaria is an insect borne disease caused by Plasmodium Although malaria has been effectively prevented and controlled in China, the number of patients continues to decline When malaria is still prevalent in 102 countries and regions, the World Health Organization (who) estimates that there are 2 billion people living in epidemic areas, especially in Africa, Southeast Asia and some countries in central and South America, the international market demand for antimalarial drugs is still large The high-tech industrialization and internationalization project of the company's new compound antimalarial drug Arco is a high-tech project included in the national high-tech industry development project plan and the national fund subsidy plan In 2007, the second extraordinary general meeting of shareholders of the company approved to invest part of the surplus funds raised from the initial public offering into the project The achievement of the clinical research results is an important step in the successful promotion of the project General name of drug: compound naphthoquine phosphate tablet trade name: Kunming Pharmaceutical Chinese Pinyin: fufanglinsuanfenpian character tablet function main treatment malaria specification About 5% of the patients had nausea and stomach discomfort after taking 8 tablets of adverse reactions; some patients may have a transient slight rise of GPT or gsamt, which can return to normal after stopping taking medicine It is forbidden to use this product in patients with allergy, severe liver and kidney dysfunction, and pregnant women within 5 months of pregnancy Precautions: use with caution in patients with liver and kidney dysfunction Because naphthoquine phosphate has accumulation effect, do not reuse the drug within 10 days Drug interaction this product is a compound preparation, containing artemisinin and naphthoquine phosphate In the animal model, the synergism index of the antagonistic strain was 8.2, but the toxicity was only additive In the clinical trial, this product is used in combination with sedatives or antibiotics, without adverse effects Approval No.: gyzz h20050270 manufacturer Kunming Pharmaceutical Group Co., Ltd